Sacituzumab Govitecan (Solution) provides a research-grade antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (Trop-2) and specifically combines a Trop-2-directed monoclonal antibody with the topoisomerase I inhibitor payload SN-38 for ADC, oncology, and targeted drug delivery research.
Key Features and Benefits
- Antibody-Drug Conjugate: Combines a Trop-2-targeting monoclonal antibody with a cytotoxic small-molecule payload.
- Trop-2 Targeting: Supports research involving Trop-2 expression, binding, internalization, and targeted delivery mechanisms.
- SN-38 Payload: Incorporates SN-38, an active metabolite of irinotecan and a topoisomerase I inhibitor.
- Targeted Payload Delivery: Enables investigation of antibody-mediated delivery of SN-38 to Trop-2-expressing cells.
- ADC Research Platform: Supports studies of ADC activity, target engagement, cellular uptake, and payload effects.
- Solution Format: Provides Sacituzumab Govitecan in solution form specifically for convenient experimental use and assay preparation.
- Oncology Research: Supports investigation of Trop-2 biology and ADC mechanisms specifically in cancer research models.
Applications
- ADC Research: Supports studies of antibody-drug conjugate targeting, internalization, and payload delivery.
- Trop-2 Research: Useful for investigating Trop-2 expression, function, and antibody-mediated targeting.
- Cancer Biology Research: Supports studies involving Trop-2-positive cancer models and related cellular pathways.
- Targeted Drug Delivery: Useful for investigating antibody-mediated delivery of cytotoxic payloads.
- Cell-Based Assays: Supports evaluation of binding, internalization, cellular response, and ADC activity.
- Mechanism-of-Action Studies: Especially useful for studying Trop-2 targeting and SN-38-mediated topoisomerase I inhibition.
- Comparative ADC Research: Supports evaluation of ADC design, targeting strategies, and experimental performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Sacituzumab Govitecan (Solution) combines Trop-2-directed antibody targeting with an SN-38 payload and specifically supports ADC development, Trop-2 research, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
